Event Type: The disclosure intimates scheduled Analyst/Institutional Investor Meetings, including one-on-one meetings and conference participation.
Meeting Schedule:
- June 01, 2026: One-on-One Meeting with Carnelian Asset Management
- June 08, 2026: Participation in ICICI Securities India Investor Conference 2026, involving both One-on-One and Group Meetings
Regulatory Basis: The intimation is made pursuant to Regulation 30 read with Part A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Schedule Flexibility: The company explicitly states that "The schedule of the above-mentioned meetings is subject to change, and the change may occur due to exigencies on the part of the Investor/ Analyst/ Company."
Management Participants: No specific management participants or their designations are disclosed in this announcement.
Presentation Materials: The announcement does not indicate whether any presentation, earnings deck, transcript, or recording will be made available.
UPSI Statement: The document does not contain any specific statement regarding the sharing or non-sharing of unpublished price sensitive information (UPSI).
Financial Information: No financial highlights, guidance references, or presentation summaries are included in this disclosure.
Additional Notes Section:
Attachments: No attachments are mentioned in this disclosure.
Financial Data Disclosure: Explicitly confirm that no financial data, figures, or performance metrics were disclosed in this announcement.
Compliance Officer: The disclosure is digitally signed by Pallerlamudi Sampath Kumar, Company Secretary & Compliance Officer of Gland Pharma Limited.